Logo
x

Search

Subscribe Now

bms

BMS Reports Topline Data from Two Pivotal P-III Studies of Sotyktu (Deucravacitinib) for Treating Psoriatic Arthritis (PsA)

BMS Reports Topline Data from Two Pivotal P-III Studies of Sotyktu (Deucravacitinib) for Treating Psoriatic Arthritis (PsA)

  • December 25, 2024
BMS Reports the EC’s Approval of Opdivo (Nivolumab) Plus Yervoy (Ipilimumab) as a 1L Treatment of MSI-H/dMMR Metastatic Colorectal Cancer (mCRC)

BMS Reports the EC’s Approval of Opdivo (Nivolumab) Plus Yervoy (Ipilimumab) as a 1L Treatment of MSI-H/dMMR Metastatic Colorectal...

  • December 24, 2024
BMS’ Opdivo + Yervoy Receives the CHMP’s Positive Opinion as a 1L Treatment of Metastatic Colorectal Cancer

BMS’ Opdivo + Yervoy Receives the CHMP’s Positive Opinion as a 1L Treatment of Metastatic Colorectal Cancer

  • November 18, 2024
BMS’ Repotrectinib Gains the CHMP’s Positive Opinion to Treat Advanced ROS1+ NSCLC and NTRK+ Solid Tumors

BMS’ Repotrectinib Gains the CHMP’s Positive Opinion to Treat Advanced ROS1+ NSCLC and NTRK+ Solid Tumors

  • November 15, 2024
PharmaShots Weekly Snapshots (September 30 – October 04, 2024)

PharmaShots Weekly Snapshots (September 30 – October 04, 2024)

  • October 4, 2024
BMS Reports the US FDA’s Approval of Opdivo Plus CT as a Neoadjuvant Treatment of Resectable Non-Small Cell Lung Cancer (NSCLC)

BMS Reports the US FDA’s Approval of Opdivo Plus CT as a Neoadjuvant Treatment of Resectable Non-Small Cell Lung Cancer (NSCLC)

  • October 4, 2024
Image

Incisive News in 3 Shots.

Contact Us

Our Information

Follow Us

Copyright © 2024 PharmaShots - All Rights Reserved.